Brief: Inhibikase Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Period Activity
12/08/2022 23:16
Aug 12 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* Q2 LOSS PER SHARE $0.18
* INHIBIKASE THERAPEUTICS - EXPECTS EXISTING CASH WILL BE
SUFFICIENT TO FUND NORMAL OPERATIONS AND CAPITAL EXPENDITURE
REQUIREMENTS THROUGH DEC. 31, 2023
Source text for Eikon: ID:nPn72j5Y3a
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary